- Version
- Download 78554
- File Size 0.00 KB
- File Count 1
- Create Date January 14, 2025
- Last Updated January 14, 2025
The Latest topics of Standards of Care in Diabetes 2025: Focusing on GLP-1RA
Hiroshi Bando1,2iD*, Michael Wood2, Koji Ebe2,3
1Medical Research/Tokushima University, Tokushima, Japan
2Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Kyoto, Japan
3Takao Hospital, Kyoto, Japan
Corresponding Author: Hiroshi Bando ORCID iD
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 13 December 2024; Accepted date: 26 December 2024; Published date: 31 December 2024
Citation: Bando H, Wood M, Ebe K. The Latest topics of Standards of Care in Diabetes 2025: Focusing on GLP-1RA. Asp Biomed Clin Case Rep. 2024 Dec 31;8(1):34-37.
Copyright © 2024 Bando H, Wood M, Ebe K. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
Keywords: American Diabetes Association, Standards of Care in Diabetes-2025, Glucagon-like Peptide-1 Receptor Agonist, Alzheimer Disease, Parkinson's Disease
Abbreviations: ADA: American Diabetes Association; GLP-1RA: Glucagon-like Peptide-1 Receptor Agonist; AD: Alzheimer Disease; PD: Parkinson's Disease
Abstract
The American Diabetes Association (ADA) presented the Standards of Care in Diabetes-2025 online in December 2024. The authors immediately reviewed and provided perspectives on the latest developments regarding glucagon-like peptide-1 receptor agonists (GLP-1RA). Some newly added content about GLP-1RA is included, such as its application for heart failure with preserved ejection fraction (HFpEF), obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and metabolic dysfunction-associated steatohepatitis (MASH). Concurrent use of DPP-4 inhibitors (DPP-4i) with GLP-1RA (GIP/GLP-1RA) is not recommended due to a lack of additional glucose-lowering effects beyond GLP-1RA alone. GLP-1RA is expected to demonstrate various positive clinical effects.